Quince Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy rating on the stock and has a $6.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors that highlight the potential of Quince Therapeutics. The company is advancing its encapsulated dexamethasone sodium phosphate (eDSP) treatment for ataxia-telangiectasia (A-T) into a Phase 3 trial, which has completed enrollment and is expected to report top-line data in the first quarter of 2026. This upcoming data release represents a significant potential inflection point for the company’s stock.
Additionally, Quince Therapeutics has a solid financial position, ending the second quarter of 2025 with approximately $35 million in cash, which is projected to sustain operations through the data release. The company’s strategic acquisition of EryDel and its AIDE technology platform, along with the promising results from prior studies, further bolster the likelihood of success. The recent rise in Quince’s stock price, alongside a recovering biotech sector, also supports the Buy rating, as the company appears well-positioned to capitalize on favorable regulatory trends and investor interest in rare diseases.
In another report released on September 26, Citizens JMP also reiterated a Buy rating on the stock with a $8.00 price target.
QNCX’s price has also changed moderately for the past six months – from $1.270 to $1.620, which is a 27.56% increase.